DIAGNOSTIC_TEST
BNP
Measurement of plasma NT-proBNP level.
Association of Plasma N-terminal Pro-Brain Natriuretic Peptide Levels With the Burden of Coronary Artery Disease
Status
Recruiting
Phase
Not applicable
Enrollment
800
Locations
2
Results
Not posted
Publications
0
Study summary
What the protocol is testing.
This study aim to investigate the association between plasma NT-proBNP levels and the presence, extent and severity of stenosis in patients with suspected coronary artery disease.
Full detailed description
The investigators prospectively measured plasma NT-proBNP levels in consecutive patients referred to the center for elective diagnostic coronary angiography due to symptoms or signs of coronary artery disease over a two- year period. Patients with conditions known to elevate NT-proBNP levels, including heart failure, severe valvular disease, atrial fibrillation, severe chronic kidney disease (eGFR \< 30 mL/min), prior coronary artery bypass grafting, or age over 80 years, were excluded.
Interventions
Treatment arms and agents.
Timeline
From registration to results.
First posted
Jun 10, 2025
Study start
Sep 1, 2021
Primary completion
Jun 29, 2025
Study completion
Jul 31, 2025
Results posted
Not reported
Registry updated
Jun 10, 2025
Outcomes
What the study measures.
Primary outcomes
Association between plasma NT-proBNP levels and the presence, extension and severity of angiographic lesions in patients with suspected CAD.
Time frame · Plasma NT-proBNP levels are quantified on the morning before coronary angiography. The CAD burden is independently evaluated by two experienced interventional cardiologists periprocedurally and immediately after the coronary angiography.
Plasma NT-proBNP levels are quantified on the morning before coronary angiography using a highly sensitive electrochemiluminescence immunoassay (ECLIA) method (NT-proBNP, Roche Diagnostics, Germany), employing the Roche Modular Analytics E170 immunoassay analyzer AL. The aim of this study is to explore the association between these levels and the presence (critical vs non-critical), location (prognostic vs non-prognostic), severity (\>70%, 70-99%, 100%) and extent of obstructive lesions detected in a contemporary cohort of patients undergoing coronary angiography for suspected CAD. Coronary angiograms are independently evaluated by two experienced interventional cardiologists (C.G. and C.G.) who are blinded to the NT-proBNP levels.
Secondary outcomes
Not reported in the indexed record.
Eligibility
Who can take part.
- Minimum age
- 18 Years
- Maximum age
- Not reported
- Sex
- ALL
- Healthy volunteers
- No
Inclusion Criteria: * patient referred for elective coronary angiography due to suspected CAD. * NT-proBNP measurement during hospitalization Exclusion Criteria: * heart failure * severe valvular disease * atrial fibrillation * severe chronic kidney disease (eGFR \< 30 mL/min) * prior coronary artery bypass grafting * age over 80 years
Study locations
2 registered sites.
Italy. Showing up to 24 locations stored in the fast local snapshot.
IRCCS San Raffaele Hospital
Milan, Italy, Italy
IRCCS San Raffaele Hospital
Milan, Italy, Italy
Publications
Results and literature.
No PMID-linked publications were present in this registry snapshot.
Related trials
More studies on Nesiritide.
NCT IDStudyPhase / statusEnrollmentUpdated
PRIMARY-HF: Heart Failure Screening in Primary Care Using Point-of- Care
Universidade do Porto · Heart Failure
Not applicable
Recruiting
160
2026-07
Boston Medical Center Ultrasound Decongestion Study in Heart Failure
Boston Medical Center · Congestive Heart Failure · Volume Overload
Not applicable
Not yet recruiting
200
2026-06
Measurement Of NT-proBNP to Predict Outcomes in Surgery
Norfolk and Norwich University Hospitals NHS Foundation Trust · Vascular Surgical Procedure
Not applicable
Recruiting
200
2026-06
rhBNP for Prevention of Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI)
China National Center for Cardiovascular Diseases · AKI - Acute Kidney Injury · Cardiac Surgical Procedures
Phase 4
Not yet recruiting
694
2026-06
Utilising AI Analysis of Sounds To prEdict heaRt failurE decOmpensation
Cambridge University Hospitals NHS Foundation Trust · Heart Failure
Not applicable
Recruiting
250
2026-05
Venous Excess and Lung Ultrasound During Continuous Kidney Replacement Therapy in Critically Ill Patients
Chulalongkorn University · Acute Kidney Failure Stage 3
Not applicable
Completed
100
2026-05
Spironolactone Therapy in Chronic Stable Right HF Trial
Ottawa Heart Institute Research Corporation · Chronic Right-Sided Heart Failure · Pulmonary Arterial Hypertension
Phase 4
Completed
15
2026-05
Secondary Use of PARALLEL-HF Data
Novartis · Chronic Heart Failure and Reduced Ejection Fraction (HFrEF)
Not applicable
Completed
236
2026-04
Related PeptideStat pages
Put the record in context.
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.